<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02258074</url>
  </required_header>
  <id_info>
    <org_study_id>DK099877-C</org_study_id>
    <nct_id>NCT02258074</nct_id>
  </id_info>
  <brief_title>The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE</brief_title>
  <acronym>COMBINE</acronym>
  <official_title>The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jennifer Gassman</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The COMBINE clinical trial is a pilot study evaluating the effects of nicotinamide and
      lanthanum carbonate on serum phosphate and fibroblast growth factor 23 (FGF23) in patients
      with Chronic Kidney Disease (CKD) stages 3-4.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Since this is a Pilot Study, the primary outcome measures is feasibility. The clinical outcome measure is change from baseline to 12 months in serum phosphate and FGF23 levels</measure>
    <time_frame>Baseline, Month 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in bone and mineral metabolism markers</measure>
    <time_frame>Baseline, Month F12</time_frame>
    <description>Bone and mineral metabolism markers assessed by changes in parathyroid hormone (PTH), calcitriol, klotho, N terminal propeptide of Type 1 procollagen (P1NP) and Tartrate-resistant acid phosphatase (Trap-5b) levels over 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in surrogate measures of cardiovascular disease (CVD) risk over 12 months</measure>
    <time_frame>Baseline, Month F12</time_frame>
    <description>CVD risk assessed by Cardiac Magnetic Resonance Imaging (MRI)-measured changes in left ventricular (LV) mass index, LV end diastolic volume, and left atrial volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in surrogate measures of CKD progression and inflammation, by changes in intra-renal oxygenation and fibrosis over 12 months</measure>
    <time_frame>Baseline, Month F12</time_frame>
    <description>CKD progression and inflammation, by changes in intra-renal oxygenation and fibrosis as assessed by gadolinium-free blood oxygenation level dependent (BOLD) MRI and diffusion-weighted MRI and changes in glomerular filtration (GFR), albuminuria and C reactive protein (CRP) and Interleukin 6 (IL-6) over 12 months.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline in brain natriuretic peptide measure of cardiovascular disease (CVD) risk over 12 months</measure>
    <time_frame>baseline, Month F12</time_frame>
    <description>CVD risk assessed by change in level of brain natriuretic peptide (pg/mL) (BNP) from baseline to Month F12.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in troponin T measure of cardiovascular risk (CVD) risk over 12 months.</measure>
    <time_frame>baseline, Month F12</time_frame>
    <description>CVD risk assessed by change in level of troponin T (ng/mL) from baseline to Month F12.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in cholesterol measure of cardiovascular disease (CVD) risk over 12 months</measure>
    <time_frame>baseline, Month F12</time_frame>
    <description>CVD risk assessed by change in level of cholesterol (mg/dl) from baseline to Month F12.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in asymmetric dimethylarginine (ADMA) measure of cardiovascular disease (CVD) risk over 12 months.</measure>
    <time_frame>baseline, Month F12</time_frame>
    <description>CVD risk assessed by change in level of asymmetric dimethylarginine (Î¼mol/L) (ADMA) from baseline to Month F12.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline bone and mineral marker parathyroid hormone (PTH) over 12 months.</measure>
    <time_frame>baseline, Month F12</time_frame>
    <description>Bone and mineral metabolism marker assessed by change in parathyroid hormone (pg/mL) (PTH) levels from baseline to 12 months.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline bone and mineral marker calcitriol over 12 months.</measure>
    <time_frame>baseline, Month F12</time_frame>
    <description>Bone and mineral metabolism marker assessed by change in calcitriol (pg/mL) levels from baseline to 12 months.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline bone and mineral marker klotho over 12 months.</measure>
    <time_frame>baseline, Month F12</time_frame>
    <description>Bone and mineral metabolism marker assessed by change in klotho levels from baseline to 12 months.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline bone and mineral marker N terminal propeptide of Type 1 procollagen (P1NP) over 12 months.</measure>
    <time_frame>baseline, Month F12</time_frame>
    <description>Bone and mineral metabolism marker assessed by change in N terminal propeptide of Type 1 procollagen (pg/mL) (P1NP) levels from baseline to 12 months.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline bone and mineral marker Tartrate-resistant acid phophatase (Trap-5b) over 12 months.</measure>
    <time_frame>baseline, Month F12</time_frame>
    <description>Bone and mineral metabolism marker assessed by change in Tartrate-resistant acid phophatase (U/L) (Trap-5b) levels from baseline to 12 months.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in surrogate measures of CKD progression and inflammation, by changes in intra-renal oxygenation and fibrosis over 12 months.</measure>
    <time_frame>baseline, Month F12</time_frame>
    <description>CKD progression and inflammation, by changes in intra-renal oxygenation and fibrosis as assessed by gadolinium-free blood oxygenation level dependent (BOLD) MRI and diffusion-weighted MRI.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in surrogate measures of CKD progression and inflammation, by changes in glomerular filtration (GFR) over 12 months.</measure>
    <time_frame>baseline, Month F12</time_frame>
    <description>CKD progression and inflammation, by changes in intra-renal oxygenation and fibrosis as assessed by glomerular filtration rate mL/min/1.73m2 (GFR) over 12 months.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in surrogate measures of CKD progression and inflammation, by changes in albumininuria over 12 months.</measure>
    <time_frame>baseline, Month F12</time_frame>
    <description>CKD progression and inflammation, by changes in intra-renal oxygenation and fibrosis as assessed by change in albuminuria over 12 months.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in surrogate measures of CKD progression and inflammation, by change in C reative protein (CRP) over 12 months.</measure>
    <time_frame>baseline, Month F12</time_frame>
    <description>CKD progression and inflammation, by changes in intra-renal oxygenation and fibrosis as assessed by change in C reative protein (mg/dL) (CRP) over 12 months.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in surrogate measures of CKD progression and inflammation, by change in Interleukin 6 (IL-6) over 12 months.</measure>
    <time_frame>baseline, Month F12</time_frame>
    <description>CKD progression and inflammation, by changes in intra-renal oxygenation and fibrosis as assessed by change in Interleukin 6 (pg/mL) (IL-6) over 12 months.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">205</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Lanthanum carbonate + nicotinamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One nicotinamide 750 mg capsule by mouth twice daily (1500 mg) for 12 months. Two lanthanum carbonate 500 mg capsules by mouth with each meal (3000 mg) for 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lanthanum carbonate + nicotinamide placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two lanthanum carbonate 500 mg capsules by mouth with each meal (3000 mg) for 12 months. One Placebo (for nicotinamide) 750 mg capsule by mouth twice daily (1500 mg) for 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lanthanum carbonate placebo and nicotinamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One nicotinamide 750 mg capsule by mouth twice daily (1500 mg) for 12 months. Two Placebo (for lanthanum carbonate) 500 mg capsules by mouth with each meal (3000 mg) for 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lanthanum carbonate placebo and nicotinamide placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One Placebo (for nicotinamide) 750 mg capsule by mouth twice daily (1500 mg) for 12 months. Two Placebo (for lanthanum carbonate) 500 mg capsules by mouth with each meal (3000 mg) for 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotinamide</intervention_name>
    <arm_group_label>Lanthanum carbonate + nicotinamide</arm_group_label>
    <arm_group_label>Lanthanum carbonate placebo and nicotinamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanthanum Carbonate</intervention_name>
    <arm_group_label>Lanthanum carbonate + nicotinamide</arm_group_label>
    <arm_group_label>Lanthanum carbonate + nicotinamide placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for Nicotinamide)</intervention_name>
    <description>Sugar pill manufactured to mimic Nicotinamide 750 mg capsule</description>
    <arm_group_label>Lanthanum carbonate + nicotinamide placebo</arm_group_label>
    <arm_group_label>Lanthanum carbonate placebo and nicotinamide placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for lanthanum carbonate)</intervention_name>
    <description>Sugar pill manufactured to mimic Lanthanum Carbonate 500 mg capsule</description>
    <arm_group_label>Lanthanum carbonate placebo and nicotinamide</arm_group_label>
    <arm_group_label>Lanthanum carbonate placebo and nicotinamide placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with estimated glomerular filtration rate (eGFR) 20-45 ml/min/1.73m2

          2. Age 18-85 years

          3. Serum phosphate â¥ 2.8 mg/dL

          4. Platelet count â¥ 125,000/mm3

          5. Able to provide consent

          6. Able to travel to study visits

          7. Able to eat at least two meals a day

          8. In the opinion of the site investigator, willing and able to follow the study
             treatment regimen and comply with the site investigator's recommendations.

        Exclusion Criteria:

          1. History of allergic reaction to nicotinamide, niacin (excluding flushing),
             multivitamin preparations, or lanthanum carbonate

          2. Liver disease, defined as known cirrhosis by imaging or physician diagnosis,
             documented alcohol use &gt; 14 drinks/week, or aspartate aminotransferase (AST), alanine
             aminotransferase (ALT), alkaline phosphatase, or total bilirubin concentrations &gt; 2
             times the upper limit of the local laboratory reference range

          3. Creatine kinase (CK) concentrations &gt; 2 times the upper limit of the local laboratory
             reference range

          4. Major hemorrhagic event within the past six months requiring in-patient admission

          5. Blood or platelet transfusion within the past six months

          6. Secondary hyperparathyroidism (PTH &gt; 5 times the upper limit of normal range for the
             laboratory) or currently taking cinacalcet (Sensipar)

          7. Current, clinically significant malabsorption, as determined at the discretion of the
             site investigator

          8. Anemia (screening Hg &lt; 9.0 g/dl)

          9. Serum albumin &lt; 2.5 mg/dl

         10. Anticipated initiation of dialysis or kidney transplantation within 12 months as
             assessed by and at the discretion of the site investigator.

         11. Use of immunosuppressive medications (stable oral steroids â¤ 10 mg of prednisone/day
             or inhaled steroids are exempted)

         12. In the opinion of the site investigator, active abuse of alcohol or drugs

         13. Recent (within the last 14 days) initiation or change in dose of treatment with 1,25
             (OH)2 vitamin D or active vitamin D analogues (paricalcitol or hectorol). Patients on
             stable doses of these agents initiated more than 14 days prior to screening are
             eligible to participate.

         14. Current or recent treatment (within the last 14 days) with phosphate binder or
             niacin/nicotinamide &gt; 100 mg/day

         15. Current participation in another clinical trial or other interventional research

         16. Currently taking investigational drugs

         17. Institutionalized individuals, including prisoners and nursing home residents

         18. Malignancy requiring therapy within 2 years (basal or squamous cell skin carcinoma and
             localized prostate cancer are exempted)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael F. Flessner, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John W. Kusek, PhD</last_name>
    <role>Study Director</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jennifer J Gassman, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Data Coordinating Center, Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Linda F Fried, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California at San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Nephrology Research</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Washington University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthShore University Health System</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah VA</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2014</study_first_submitted>
  <study_first_submitted_qc>October 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2014</study_first_posted>
  <last_update_submitted>October 31, 2017</last_update_submitted>
  <last_update_submitted_qc>October 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</investigator_affiliation>
    <investigator_full_name>Jennifer Gassman</investigator_full_name>
    <investigator_title>Principal Investigator-Data Coordinating Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

